Arkansas Sues Pharma Over Alleged 340B Drug Discount Conspiracy
Arkansas sued pharmaceutical companies alleging a conspiracy to undermine the 340B drug discount program.
Why it matters: This lawsuit impacts legal compliance and enforcement of the 340B program, vital for hospitals serving low-income communities. It highlights ongoing litigation reshaping access to federal drug discounts and regulatory interpretation.
- Arkansas filed its lawsuit on July 22, 2026, alleging pharma firms conspired to weaken the federal 340B Drug Pricing Program.
- The 340B program requires drug manufacturers to provide discounts to hospitals and clinics serving underserved, low-income populations.
- In March 2024, the 8th Circuit upheld Arkansas' 340B Drug Pricing Nondiscrimination Act protecting contract pharmacy arrangements (arkansas lawsuit link).
- Other legal actions include the American Hospital Association's December 2025 suit against the 340B Rebate Model Pilot Program and AbbVie’s April 2026 challenge to 340B patient definitions.
On July 22, 2026, Arkansas filed a lawsuit accusing several pharmaceutical companies of conspiring to undermine the federal 340B Drug Pricing Program, which mandates discounted drug prices for healthcare providers serving vulnerable, low-income patients.
The 340B program, created in 1992, enables eligible hospitals and clinics to purchase outpatient drugs at reduced prices, thereby supporting community health services. Arkansas’ suit alleges coordinated actions that restrict access to these discounts.
In a key precedent, the U.S. Court of Appeals for the 8th Circuit upheld Arkansas' 340B Drug Pricing Nondiscrimination Act in March 2024. This law bars manufacturers from limiting providers’ use of 340B discounts through contract pharmacies. The court found the law facilitates rather than obstructs compliance with the federal program.
Related lawsuits continue to shape the legal landscape. The American Hospital Association (AHA) and others filed suit in December 2025 to block the 340B Rebate Model Pilot Program, which seeks to adjust manufacturer rebates and has raised concerns over impacts on patient care.
In April 2026, pharma company AbbVie challenged the federal definition of "patient" for program eligibility, contesting how 340B benefits are administered. Separately, hospitals owned by major health systems sued CVS Health in May 2026, alleging CVS improperly redirected $250 million in savings tied to 340B discounts.
Rick Pollack, president of the AHA, underscored the program’s significance: the 340B program "plays a critical role in helping eligible hospitals provide a wide range of comprehensive services and low-cost drugs to vulnerable patients and communities." The ongoing lawsuits, including Arkansas’, reflect persistent tensions regarding implementation, access, and the financial effects of 340B.
These legal developments bear directly on compliance strategies and regulatory enforcement, influencing how hospitals and clinics will manage drug costs and maintain affordable care for underserved populations.
By the numbers:
- July 22, 2026 — Date Arkansas filed the 340B-related lawsuit
- March 2024 — 8th Circuit upheld Arkansas’ 340B Nondiscrimination Act
- $250 million — Alleged 340B savings redirected by CVS in May 2026 lawsuit
Yes, but: The identities of some pharmaceutical companies in the Arkansas suit remain undisclosed, and allegations of conspiracy have yet to be proven in court.
What's next: Legal challenges around the 340B program, including the AbbVie and CVS cases, are ongoing and may prompt further regulatory guidance or congressional action.